Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep

• Published in: JCI insight Vol. 6; no. 24
• Main Authors: Ferguson, Chantal M, Godinho, Bruno Mdc, Alterman, Julia F, Coles, Andrew H, Hassler, Matthew, Echeverria, Dimas, Gilbert, James W, Knox, Emily G, Caiazzi, Jillian, Haraszti, Reka A, King, Robert M, Taghian, Toloo, Puri, Ajit, Moser, Richard P, Gounis, Matthew J, Aronin, Neil, Gray-Edwards, Heather, Khvorova, Anastasia
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 22.12.2021; American Society for Clinical investigation
• Subjects: Animals; Drug Administration Routes; Genetic Therapy - methods; Neuroscience; Resource and Technical Advance; RNA, Small Interfering - administration & dosage; Sheep; Neuroscience; Gene therapy; RNA processing; Neurodegeneration
• ISSN: 2379-3708; 2379-3708
• DOI: 10.1172/jci.insight.152203

siRNAs comprise a class of drugs that can be programmed to silence any target gene. Chemical engineering efforts resulted in development of divalent siRNAs (di-siRNAs), which support robust and long-term efficacy in rodent and nonhuman primate brains upon direct cerebrospinal fluid (CSF) administration. Oligonucleotide distribution in the CNS is nonuniform, limiting clinical applications. The contribution of CSF infusion placement and dosing regimen on relative accumulation, specifically in the context of large animals, is not well characterized. To our knowledge, we report the first systemic, comparative study investigating the effects of 3 routes of administration - intrastriatal (i.s.), i.c.v., and intrathecal catheter to the cisterna magna (ITC) - and 2 dosing regimens - single and repetitive via an implanted reservoir device - on di-siRNA distribution and accumulation in the CNS of Dorset sheep. CSF injections (i.c.v. and ITC) resulted in similar distribution and accumulation across brain regions. Repeated dosing increased homogeneity, with greater relative deep brain accumulation. Conversely, i.s. administration supported region-specific delivery. These results suggest that dosing regimen, not CSF infusion placement, may equalize siRNA accumulation and efficacy throughout the brain. These findings inform the planning and execution of preclinical and clinical studies using siRNA therapeutics in the CNS.